Dr. John Cush RheumNow
4 years ago
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine.
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Dr. John Cush RheumNow
4 years ago
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow
4 years ago
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
https://t.co/ieaYyznlec https://t.co/YafTOxh8Cr
Dr. John Cush RheumNow
4 years ago
Update to Axial Spondyloarthritis Guidance
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
https://t.co/XQId2RIaVz https://t.co/vNRYSV2jRh
Dr. John Cush RheumNow
4 years ago
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
https://t.co/frGedFHVuU https://t.co/I9B4YjcqLa
Dr. John Cush RheumNow
4 years ago
Increasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), PsA and SpA patients in England.
https://t.co/Rtt5dvFc17 https://t.co/rPsvq3nlXl
Dr. John Cush RheumNow
4 years ago
Retrospective study of 75 knee OA pts w/ SF aspiration and MRI showed Median SF WBC =284, w/ higher SF WBC w/medium/large effusions. Despite this trend, SF WBC did not strongly correlate w/ MRI inflammation (effusions or synovitis) https://t.co/6suIGJNLdW https://t.co/gNd1Dai4SI
Dr. John Cush RheumNow
4 years ago
Increasing Risk of Lupus Nephritis
A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population.
https://t.co/iQ00MnFe2N https://t.co/3z9UrccdM1
Dr. John Cush RheumNow
4 years ago
PSOAS study of 354 with long-standing ankylosing spondylitis & SI radiographic changes; but 23 lacked syndesmophytes. Lack of fusion was more likely in women & w/younger age of Sx onset. All were B27+, thus B27 may be assoc w/ SI dz, not spinal dz. https://t.co/EpDW6wTZNr https://t.co/IHRvdkDiaD
Dr. John Cush RheumNow
4 years ago
Listen to the FDA Drug Safety Podcast (for HCPs). On the Risk of Serious Adverse events with JAK Inhibitors (based on their HCP safety alert from 9/21/2021). 4 min long, basic info, not alot of depth...but its from the FDA. https://t.co/0Hns5bDU2A https://t.co/mRKi8NEKGW
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
The revision included 15 recommendations in total. Of these, 11 either remained the same from earlier editions or involved minor wording changes. Two, however, differed substantially, and two others were entirely new.
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
